David G. Orloff

1.9k total citations
26 papers, 1.5k citations indexed

About

David G. Orloff is a scholar working on Surgery, Economics and Econometrics and Molecular Biology. According to data from OpenAlex, David G. Orloff has authored 26 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Surgery, 7 papers in Economics and Econometrics and 6 papers in Molecular Biology. Recurrent topics in David G. Orloff's work include Lipoproteins and Cardiovascular Health (12 papers), Pharmaceutical Economics and Policy (6 papers) and Immune Cell Function and Interaction (5 papers). David G. Orloff is often cited by papers focused on Lipoproteins and Cardiovascular Health (12 papers), Pharmaceutical Economics and Policy (6 papers) and Immune Cell Function and Interaction (5 papers). David G. Orloff collaborates with scholars based in United States, Australia and Netherlands. David G. Orloff's co-authors include Richard D. Klausner, Stuart J. Frank, Allan M. Weissman, Chisei Ra, Jean‐Pierre Kinet, Mladen Merćep, Jonathan D. Ashwell, Therèse Heinonen, Jean‐Claude Tardif and Peter Libby and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

David G. Orloff

25 papers receiving 1.5k citations

Peers

Countries citing papers authored by David G. Orloff

Since Specialization

Citations

This map shows the geographic impact of David G. Orloff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David G. Orloff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David G. Orloff more than expected).

Fields of papers citing papers by David G. Orloff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David G. Orloff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David G. Orloff. The network helps show where David G. Orloff may publish in the future.

Co-authorship network of co-authors of David G. Orloff

This figure shows the co-authorship network connecting the top 25 collaborators of David G. Orloff. A scholar is included among the top collaborators of David G. Orloff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David G. Orloff. David G. Orloff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance 2016 ·Journal of clinical lipidology ·Paul D. Thompson, Diane MacDougall, Roger S. Newton, Janice R. Margulies, Jeffrey C. Hanselman, David G. Orloff, James M. McKenney, Christie M. Ballantyne	118
2	Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia 2016 ·Cardiology ·John J.P. Kastelein, Jonas Hallén, (unknown), David A. Fraser, Rong Zhou, Svein Olaf Hustvedt, David G. Orloff, Harold Bays	11
3	ETC-1002 LOWERS LDL-C MORE THAN EZETIMIBE IN PATIENTS WITH HYPERCHOLESTEROLEMIA WITH OR WITHOUT STATIN INTOLERANCE AND HAS A SIMILAR SAFETY AND TOLERABILITY PROFILE 2015 ·Journal of the American College of Cardiology ·Paul D. Thompson, Christie M. Ballantyne, James McKenney, David G. Orloff, Diane MacDougall, Janice R. Margulies, Jeffrey C. Hanselman, Roger S. Newton	5
4	Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial 2015 ·Journal of clinical lipidology ·Harold Bays, Jonas Hallén, (unknown), David A. Fraser, Rong Zhou, Svein Olaf Hustvedt, David G. Orloff, John J.P. Kastelein	24
5	Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial 2015 ·Lipids in Health and Disease ·Richard L. Dunbar, Stephen J. Nicholls, Kevin C. Maki, Eli M. Roth, David G. Orloff, Danielle Curcio, Judith Johnson, Douglas Kling, Michael H. Davidson	45
6	Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer 2013 ·Clinical Pharmacology & Therapeutics ·Jerry R. Colca, James T. VanderLugt, Wade J. Adams, (unknown), William Graham McDonald, (unknown), (unknown), David G. Orloff	61
7	A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial) 2013 ·Clinical Therapeutics ·Kevin C. Maki, David G. Orloff, Stephen J. Nicholls, Richard L. Dunbar, Eli M. Roth, Danielle Curcio, Judith Johnson, Douglas Kling, Michael H. Davidson	83
8	A HIGHLY BIOAVAILABLE OMEGA-3 FREE-FATTY ACID REDUCES NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN HIGH-RISK PATIENTS TREATED WITH A STATIN AND RESIDUAL HYPERTRIGLYCERIDEMIA (ESPRIT TRIAL) 2013 ·Journal of the American College of Cardiology ·Kevin C. Maki, David G. Orloff, Stephen J. Nicholls, Richard L. Dunbar, Eli M. Roth, Danielle Curcio, Judith Johnson, Douglas Kling, Michael H. Davidson	1
9	Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future 2007 ·Pharmacological Reviews ·James H. Revkin, Charles L. Shear, H. Pouleur, (unknown), David G. Orloff	52
10	Fixed Combination Drugs for Cardiovascular Disease Risk Reduction: Regulatory Approach 2005 ·The American Journal of Cardiology ·David G. Orloff	20
11	Regulatory issues in the approval of new drugs for diabetes mellitus, dyslipidemia, and the metabolic syndrome 2004 ·The American Journal of Cardiology ·Jonathan L. Isaacsohn, August J. Troendle, David G. Orloff	7
12	The impact of the national cholesterol education program adult treatment panel III guidelines on drug development 2002 ·The American Journal of Cardiology ·Jonathan L. Isaacsohn, Donald M. Black, August J. Troendle, David G. Orloff	5
13	A brief history of calcitonin 2002 ·The Lancet ·Eric Colman, (unknown), (unknown), David G. Orloff	17
14	Use of surrogate endpoints: a practical necessity in lipid-altering and antiatherosclerosis drug development 2001 ·The American Journal of Cardiology ·David G. Orloff	9
15	Regulatory Concerns at Various Phases of Drug Development 1998 ·The American Journal of Cardiology ·(unknown), David G. Orloff, Solomon Sobel	7
16	Update on the U.S. Food and Drug Administration Regulatory Approach to Over-the-Counter Cholesterol-Lowering Drugs 1998 ·The American Journal of Cardiology ·David G. Orloff	0
17	Glucose utilization in a patient with hepatoma and hypoglycemia. Assessment by a positron emission tomography. 1992 ·Journal of Clinical Investigation ·R C Eastman, Richard E. Carson, David G. Orloff, (unknown), James F. Perdue, Matthew M. Rechler, F Lanau, Charles T. Roberts, Jeffrey Shapiro, Jesse Roth	48
18	An iron-sulfur cluster plays a novel regulatory role in the iron-responsive element binding protein 1992 ·BioMetals ·Tracey A. Rouault, David J. Haile, William E. Downey, Caroline C. Philpott, Careen K. Tang, Felipe Samaniego, (unknown), Ian A. Paul, David G. Orloff, Joe B. Harford, Richard D. Klausner	78
19	A regulated RNA binding protein also possesses aconitase activity. 1991 ·Proceedings of the National Academy of Sciences ·(unknown), William E. Downey, Catherine Tang, Carl Philpott, David J. Haile, David G. Orloff, Joe B. Harford, Tracey A. Rouault, Richard D. Klausner	167
20	Family of disulphide-linked dimers containing the ζ and η chains of the T-cell receptor and the γ chain of Fc receptors 1990 ·Nature ·David G. Orloff, Chisei Ra, Stuart J. Frank, Richard D. Klausner, Jean‐Pierre Kinet	206

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact